270
Participants
Start Date
December 1, 2025
Primary Completion Date
June 30, 2028
Study Completion Date
December 31, 2028
GOLP regimen
PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
Surgery
R0 resection
TDTP-RECIST
Treatment selection between continued GOLP therapy and surgical R0 resection based on TDTP-RECIST criteria.
Zhongshan hospital, Shanghai, Shanghai
Shanghai Geriatric Medical Center
OTHER
Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine
UNKNOWN
Shanghai 10th People's Hospital
OTHER
Oriental Hepatobiliary Surgery Hospital Affiliated to Naval Military Medical University
UNKNOWN
Shanghai Zhongshan Hospital
OTHER